PolyBio Research Foundation, Medford, MA, USA.
Division of Neurotherapeutics, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Nat Immunol. 2023 Oct;24(10):1616-1627. doi: 10.1038/s41590-023-01601-2. Epub 2023 Sep 4.
Millions of people are suffering from Long COVID or post-acute sequelae of COVID-19 (PASC). Several biological factors have emerged as potential drivers of PASC pathology. Some individuals with PASC may not fully clear the coronavirus SARS-CoV-2 after acute infection. Instead, replicating virus and/or viral RNA-potentially capable of being translated to produce viral proteins-persist in tissue as a 'reservoir'. This reservoir could modulate host immune responses or release viral proteins into the circulation. Here we review studies that have identified SARS-CoV-2 RNA/protein or immune responses indicative of a SARS-CoV-2 reservoir in PASC samples. Mechanisms by which a SARS-CoV-2 reservoir may contribute to PASC pathology, including coagulation, microbiome and neuroimmune abnormalities, are delineated. We identify research priorities to guide the further study of a SARS-CoV-2 reservoir in PASC, with the goal that clinical trials of antivirals or other therapeutics with potential to clear a SARS-CoV-2 reservoir are accelerated.
数以百万计的人患有长新冠或新冠后急性后遗症(PASC)。一些生物学因素已被认为是 PASC 病理的潜在驱动因素。一些 PASC 患者在急性感染后可能无法完全清除冠状病毒 SARS-CoV-2。相反,复制的病毒和/或病毒 RNA——可能有能力被翻译以产生病毒蛋白——作为“储库”在组织中持续存在。这个储库可以调节宿主的免疫反应,或将病毒蛋白释放到循环中。在这里,我们回顾了已识别出在 PASC 样本中存在 SARS-CoV-2 RNA/蛋白或免疫反应指示的 SARS-CoV-2 储库的研究。阐述了 SARS-CoV-2 储库可能导致 PASC 病理的机制,包括凝血、微生物组和神经免疫异常。我们确定了研究重点,以指导对 PASC 中 SARS-CoV-2 储库的进一步研究,目标是加速具有清除 SARS-CoV-2 储库潜力的抗病毒药物或其他治疗药物的临床试验。
Nat Immunol. 2023-10
Cochrane Database Syst Rev. 2022-11-17
Cochrane Database Syst Rev. 2021-9-2
Cochrane Database Syst Rev. 2024-12-16
Cochrane Database Syst Rev. 2022-7-22
Front Cell Infect Microbiol. 2025-8-11
Top Antivir Med. 2025-6-30
Front Public Health. 2025-7-28
Psychiatry Clin Neurosci. 2025-6-19
Front Immunol. 2025-6-3
J Hematol Oncol. 2022-8-16
J Alzheimers Dis. 2022